ADVERTISEMENT

Ajanta Pharma Q2 Results Review - Branded Generics Revenue Outperform Expectations: Systematix

New launches and an expected stable price erosion should contribute to a meaningful growth in top-line for the company supported by stable Ebitda margins, says the brokerage.

<div class="paragraphs"><p>(Source: Milivigerova/ pexels)</p></div>
(Source: Milivigerova/ pexels)
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
To continue reading this story
You must be an existing Premium User
OUR NEWSLETTERS
By signing up you agree to the Terms & Conditions of NDTV Profit